In Silico Repositioning-Chemogenomics Strategy Identifies New Drugs with Potential Activity against Multiple Life Stages of Schistosoma mansoni

PLoS Neglected Tropical Diseases

Volumn 9, Issue 1, 2015, Pages

  Neves, Bruno J ^a   Braga, Rodolpho C ^a,b   Bezerra, José C B ^a   Cravo, Pedro V L ^a,c   Andrade, Carolina H ^a  

^a FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

APRINDINE; ARTESUNATE; AURANOFIN; CINNARIZINE; CLONAZEPAM; CLOTRIMAZOLE; FLUBENDAZOLE; GENTAMICIN; GRISEOFULVIN; METHOTREXATE; NIFEDIPINE; TETRABENAZINE; ANTISCHISTOSOMAL AGENT; HELMINTH PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; BIOINFORMATICS; CHEMOGENOMICS; COMPUTER MODEL; DATA BASE; DRUG TARGETING; DRUGBANK DATABASE; GENOMICS; NONHUMAN; SCHISTOSOMA MANSONI; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; STITCH DATABASE; THERAPEUTIC TARGET DATABASE; TREMATODE LIFE CYCLE STAGE; ANIMAL; COMPUTER SIMULATION; DRUG DEVELOPMENT; DRUG EFFECTS; GENOME; LIFE CYCLE STAGE; METABOLISM; PARASITOLOGY; SCHISTOSOMIASIS MANSONI;

ANIMALS; COMPUTER SIMULATION; DRUG DISCOVERY; GENOME, HELMINTH; GENOMICS; HELMINTH PROTEINS; LIFE CYCLE STAGES; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; SCHISTOSOMICIDES;

EID: 84922256583     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003435     Document Type: Article

References (113)

1. Gryseels B, Polman K, Clerinx J, Kestens L, (2006) Human schistosomiasis. Lancet 368: 1106–1118.
2. King CH, Dickman K, Tisch DJ, (2005) Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet 365: 1561–1569.
3. Colley DG, Bustinduy AL, Secor WE, King CH, (2014) Human schistosomiasis. Lancet 383: 2253–2264 doi:10.1016/S0140-6736(13)61949-2
4. Yang Z, Grinchuk V, Smith A, Qin B, Bohl JA, et al. (2013) Parasitic nematode-induced modulation of body weight and associated metabolic dysfunction in mouse models of obesity. Infect Immun 81: 1905–1914 doi:10.1128/IAI.00053-13
5. Melman SD, Steinauer ML, Cunningham C, Kubatko LS, Mwangi IN, et al. (2009) Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni. PLoS Negl Trop Dis 3: e504 doi:10.1371/journal.pntd.0000504
6. Rollinson D, Knopp S, Levitz S, Stothard JR, Tchuem Tchuenté L-A, et al. (2013) Time to set the agenda for schistosomiasis elimination. Acta Trop 128: 423–440.
7. WHO (2014) Schistosomiasis. Fact sheet: http://www.who.int/mediacentre/factsheets/fs115/en.
8. Gobert GN, Chai M, McManus DP, (2007) Biology of the schistosome lung-stage schistosomulum. Parasitology 134: 453–460.
9. He Y-X, Salafsky B, Ramaswamy K, (2005) Comparison of skin invasion among three major species of Schistosoma. Trends Parasitol 21: 201–203.
10. Burke ML, Jones MK, Gobert GN, Li YS, Ellis MK, et al. (2009) Immunopathogenesis of human schistosomiasis. Parasite Immunol 31: 163–176.
11. World Health Organization (2012) Progress report 2001–2011 and strategic plan 2012–2020. Geneva, Switzerland.
12. Pérez del Villar L, Burguillo FJ, López-Abán J, Muro A, (2012) Systematic review and meta-analysis of artemisinin based therapies for the treatment and prevention of schistosomiasis. PLoS One 7: e45867.
13. Gönnert R, Andrews P, (1977) Praziquantel, a new board-spectrum antischistosomal agent. Z Parasitenkd 52: 129–150.
14. Ismail M, Metwally A, Farghaly A, Bruce J, Tao LF, et al. (1996) Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel. Am J Trop Med Hyg 55: 214–218.
15. Wang W, Wang L, Liang Y, (2012) Susceptibility or resistance of praziquantel in human schistosomiasis: a review. Parasitol Res 111: 1871–1877 doi:10.1007/s00436-012-3151-z
16. Gryseels B, Mbaye A, De Vlas SJ, Stelma FF, Guissé F, et al. (2001) Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence. Trop Med Int Heal 6: 864–873.
17. Chantree P, Phatsara M, Meemon K, Chaichanasak P, Changklungmoa N, et al. (2013) Vaccine potential of recombinant cathepsin B against Fasciola gigantica. Exp Parasitol 135: 102–109 doi:10.1016/j.exppara.2013.06.010
18. Food and Drug Administration (2014) FDA approvals for the first 6 months of 2014. Nat Rev Drug Discov 13: 565–565 doi:10.1038/nrd4409
19. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, et al. (2002) Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347: 1739–1746.
20. Ekins S, Williams AJ, Krasowski MD, Freundlich JS, (2011) In silico repositioning of approved drugs for rare and neglected diseases. Drug Discov Today 16: 298–310.
21. Ma D-L, Chan DS-H, Leung C-H, (2013) Drug repositioning by structure-based virtual screening. Chem Soc Rev 42: 2130–2141.
22. Li YY, Jones SJ, (2012) Drug repositioning for personalized medicine. Genome Med 4: 27.
23. Andrade CH, Salum L, Pasqualoto KFM, Ferreira EI, Andricopulo AD, (2008) Three-Dimensional Quantitative Structure-Activity Relationships for a Large Series of Potent Antitubercular Agents. Lett Drug Des Discov 5: 377–387 doi:10.2174/157018008785777289
24. Andrade CH, Pasqualoto KFM, Zaim MH, Ferreira EI, (2008) Abordagem racional no planejamento de novos tuberculostáticos: inibidores da InhA, enoil-ACP redutase do M. tuberculosis. Rev Bras ciencias Farm 44: 167–179 doi:10.1590/S1516-93322008000200002
25. Andrade CH, Salum LDB, Castilho MS, Pasqualoto KFM, Ferreira EI, et al. (2008) Fragment-based and classical quantitative structure-activity relationships for a series of hydrazides as antituberculosis agents. Mol Divers 12: 47–59 doi:10.1007/s11030-008-9074-z
26. Andrade CH, Pasqualoto KFM, Ferreira EI, Hopfinger AJ, (2009) Rational design and 3D-pharmacophore mapping of 5′-thiourea-substituted alpha-thymidine analogues as mycobacterial TMPK inhibitors. J Chem Inf Model 49: 1070–1078 doi:10.1021/ci8004622
27. Braga RC, Sabino JR, de Valeria O, Andrade CH (2010) Discovery of novel hit compounds for Trypanosoma cruzi sterol 14α-demethylase through structure-based virtual screening. Abstracts of Papers, 240th American Chemical Society National Meeting & Exposition, Boston, MA, United States, August 22–26. p. MEDI–379.
28. Andrade CH, Pasqualoto KFM, Ferreira EI, Hopfinger AJ, (2010) 3D-Pharmacophore mapping of thymidine-based inhibitors of TMPK as potential antituberculosis agents. J Comput Aided Mol Des 24: 157–172 doi:10.1007/s10822-010-9323-y
29. Andrade CH, Pasqualoto KFM, Ferreira EI, Hopfinger AJ, (2010) 4D-QSAR: perspectives in drug design. Molecules 15: 3281–3294 doi:10.3390/molecules15053281
30. Braga RC, Liao LM, Bezerra JC, Vinaud MC, Andrade CH (2012) Integrated Chemoinformatics approaches to virtual screening in the search of new lead compounds against Leishmania. Abstracts of Papers, 244th American Chemical Society National Meeting & Exposition, Philadelphia, PA, United States, August 19–23, 2012. p. CINF–46.
31. Neves BJ, Bueno R V, Braga RC, Andrade CH, (2013) Discovery of new potential hits of Plasmodium falciparum enoyl-ACP reductase through ligand- and structure-based drug design approaches. Bioorg Med Chem Lett 23: 2436–2441 doi:10.1016/j.bmcl.2013.02.006
32. Bueno R V, Toledo NR, Neves BJ, Braga RC, Andrade CH, (2013) Structural and chemical basis for enhanced affinity to a series of mycobacterial thymidine monophosphate kinase inhibitors: fragment-based QSAR and QM/MM docking studies. J Mol Model 19: 179–192 doi:10.1007/s00894-012-1527-8
33. Braga RC, Andrade CH, (2013) Assessing the Performance of 3D Pharmacophore Models in Virtual Screening: How Good are They? Curr Top Med Chem 13: 1127–1138.
34. Melo-Filho CC, Braga RC, Andrade CH, (2014) 3D-QSAR Approaches in Drug Design: Perspectives to Generate Reliable CoMFA Models. Curr Comput Aided Drug Des 10: 148–159.
35. Bueno R V, Braga RC, Segretti ND, Ferreira EI, Trossini GHG, et al. (2014) New tuberculostatic agents targeting nucleic acid biosynthesis: drug design using QSAR approaches. Curr Pharm Des 20: 4474–4485.
36. Braga RC, Alves VM, Silva AC, Nascimento MN, Silva FC, et al. (2014) Virtual Screening Strategies in Medicinal Chemistry: The state of the art and current challenges. Curr Top Med Chem 14.
37. Braga RC, Pinto EG, Martins LF, Tempone AG, Liao LM, et al. (2014) Multitarget virtual screening approach: Identification of new hit compounds against Leishmania infantum. Abstracts of Papers, 248th ACS National Meeting & Exposition, San Francisco, CA, United States, August 10–14, 2014. American Chemical Society. p. COMP–322.
38. Braga RC, Alves VM, Silva MFB, Muratov E, Fourches D, et al. (2014) Tuning hERG out: Antitarget QSAR Models for Drug Development. Curr Top Med Chem 14: 1399–1415.
39. Andrade CH, Silva DC, Braga RC (2014) In silico Prediction of Drug Metabolism by P450. Curr Drug Metab.
40. Andrade CH, Braga RC, (2014) Drug Metabolism, Toxicology Experimental Determination And Theoretical Prediction: Challenges And Perspectives From A Medicinal Chemistry Point Of View. Curr Top Med Chem 14: 1323–1324.
41. Alves VM, Braga RC, Silva MB, Muratov E, Fourches D, et al. (2014) Pred-hERG: A novel web-accessible computational tool for predicting cardiac toxicity of drug candidates. Abstracts of Papers, 248th ACS National Meeting & Exposition, San Francisco, CA, United States, August 10–14, 2014. American Chemical Society. p. CINF–40.
42. Carneiro EO, Andrade CH, Braga RC, Tôrres ACB, Alves RO, et al. (2010) Structure-based prediction and biosynthesis of the major mammalian metabolite of the cardioactive prototype LASSBio-294. Bioorg Med Chem Lett 20: 3734–3736 doi:10.1016/j.bmcl.2010.04.073
43. Braga RC, Andrade CH, (2012) QSAR and QM/MM approaches applied to drug metabolism prediction. Mini Rev Med Chem 12: 573–582.
44. Iorio F, Isacchi A, di Bernardo D, Brunetti-Pierri N, (2010) Identification of small molecules enhancing autophagic function from drug network analysis. Autophagy 6: 1204–1205.
45. Clark PM, Dawany N, Dampier W, Byers SW, Pestell RG, et al. (2012) Bioinformatics analysis reveals transcriptome and microRNA signatures and drug repositioning targets for IBD and other autoimmune diseases. Inflamm Bowel Dis 18: 2315–2333.
46. Bispo NA, Culleton R, Silva LA, Cravo P, (2013) A Systematic In Silico Search for Target Similarity Identifies Several Approved Drugs with Potential Activity against the Plasmodium falciparum Apicoplast. PLoS One 8: e59288 doi:10.1371/journal.pone.0059288
47. Caffrey CR, Rohwer A, Oellien F, Marhöfer RJ, Braschi S, et al. (2009) A comparative chemogenomics strategy to predict potential drug targets in the metazoan pathogen, Schistosoma mansoni. PLoS One 4: e4413 doi:10.1371/journal.pone.0004413
48. Zhu F, Han B, Kumar P, Liu X, Ma X, et al. (2010) Update of TTD: Therapeutic Target Database. Nucleic Acids Res 38: D787–91.
49. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, et al. (2006) DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 34: D668–72.
50. Kuhn M, Szklarczyk D, Franceschini A, von Mering C, Jensen LJ, et al. (2012) STITCH 3: zooming in on protein-chemical interactions. Nucleic Acids Res 40: D876–80.
51. Bredel M, Jacoby E, (2004) Chemogenomics: an emerging strategy for rapid target and drug discovery. Nat Rev Genet 5: 262–275.
52. Rognan D, (2007) Chemogenomic approaches to rational drug design. Br J Pharmacol 152: 38–52.
53. Protasio A V, Tsai IJ, Babbage A, Nichol S, Hunt M, et al. (2012) A systematically improved high quality genome and transcriptome of the human blood fluke Schistosoma mansoni. PLoS Negl Trop Dis 6: e1455 doi:10.1371/journal.pntd.0001455
54. Agüero F, Al-Lazikani B, Aslett M, Berriman M, Buckner FS, et al. (2008) Genomic-scale prioritization of drug targets: the TDR Targets database. Nat Rev Drug Discov 7: 900–907.
55. Hertz-Fowler C, Peacock CS, Wood V, Aslett M, Kerhornou A, et al. (2004) GeneDB: a resource for prokaryotic and eukaryotic organisms. Nucleic Acids Res 32: D339–43.
56. Dong Y, Guha S, Sun X, Cao M, Wang X, et al. (2012) Nutraceutical interventions for promoting healthy aging in invertebrate models. Oxid Med Cell Longev 2012: 718491 doi:10.1155/2012/718491
57. Agarwal P, States DJ, (1998) Comparative accuracy of methods for protein sequence similarity search. Bioinformatics 14: 40–47.
58. Ashkenazy H, Erez E, Martz E, Pupko T, Ben-Tal N, (2010) ConSurf 2010: calculating evolutionary conservation in sequence and structure of proteins and nucleic acids. Nucleic Acids Res 38: W529–33.
59. Apweiler R, Bairoch A, Wu CH, Barker WC, Boeckmann B, et al. (2004) UniProt: the Universal Protein knowledgebase. Nucleic Acids Res 32: D115–9.
60. Li W, Godzik A, (2006) Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences. Bioinformatics 22: 1658–1659.
61. Katoh K, Kuma K, Miyata T, Toh H, (2005) Improvement in the accuracy of multiple sequence alignment program MAFFT. Genome informatics 16: 22–33.
62. Pupko T, Bell RE, Mayrose I, Glaser F, Ben-Tal N, (2002) Rate4Site: an algorithmic tool for the identification of functional regions in proteins by surface mapping of evolutionary determinants within their homologues. Bioinformatics 18 Suppl 1: S71–7.
63. Mayrose I, Graur D, Ben-Tal N, Pupko T, (2004) Comparison of site-specific rate-inference methods for protein sequences: empirical Bayesian methods are superior. Mol Biol Evol 21: 1781–1791.
64. Wang Y, Xiao J, Suzek TO, Zhang J, Wang J, et al. (2012) PubChem's BioAssay Database. Nucleic Acids Res 40: D400–12 doi:10.1093/nar/gkr1132
65. Fourches D, Muratov E, Tropsha A, (2010) Trust, but verify: on the importance of chemical structure curation in cheminformatics and QSAR modeling research. J Chem Inf Model 50: 1189–1204 doi:10.1021/ci100176x
66. Landrum G (2014) RDKit: Open-source cheminformatics: http://www.rdkit.org/.
67. R Development Core Team (2008) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing.
68. Hopkins AL, Groom CR, (2002) The druggable genome. Nat Rev Drug Discov 1: 727–730.
69. Russ AP, Lampel S, (2005) The druggable genome: an update. Drug Discov Today 10: 1607–1610.
70. Edfeldt FNB, Folmer RHA, Breeze AL, (2011) Fragment screening to predict druggability (ligandability) and lead discovery success. Drug Discov Today 16: 284–287.
71. Dobson CM, (2004) Chemical space and biology. Nature 432: 824–828.
72. Lipinski C, Hopkins A (2004) Navigating chemical space for biology and medicine. Nature 432.
73. Audisio D, Messaoudi S, Ijjaali I, Dubus E, Petitet F, et al. (2010) Assessing the chemical diversity of an hsp90 database. Eur J Med Chem 45: 2000–2009.
74. Lachance H, Wetzel S, Kumar K, Waldmann H, (2012) Charting, navigating, and populating natural product chemical space for drug discovery. J Med Chem 55: 5989–6001.
75. Bon RS, Waldmann H, (2010) Bioactivity-guided navigation of chemical space. Acc Chem Res 43: 1103–1114 doi:10.1021/ar100014h
76. Berriman M, Haas BJ, LoVerde PT, Wilson RA, Dillon GP, et al. (2009) The genome of the blood fluke Schistosoma mansoni. Nature 460: 352–358 doi:10.1038/nature08160
77. Ribeiro P, Patocka N, (2013) Neurotransmitter transporters in schistosomes: structure, function and prospects for drug discovery. Parasitol Int 62: 629–638.
78. Doenhoff MJ, Cioli D, Utzinger J, (2008) Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis 21: 659–667.
79. Smout MJ, Kotze AC, McCarthy JS, Loukas A, (2010) A novel high throughput assay for anthelmintic drug screening and resistance diagnosis by real-time monitoring of parasite motility. PLoS Negl Trop Dis 4: e885.
80. Cohen CJ, Spires S, Van Skiver D, (1992) Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol 100: 703–728.
81. Singh BN, (1986) The mechanism of action of calcium antagonists relative to their clinical applications. Br J Clin Pharmacol 21 Suppl 2: 109S–121S.
82. Silva-Moraes V, Couto FFB, Vasconcelos MM, Araújo N, Coelho PMZ, et al. (2013) Antischistosomal activity of a calcium channel antagonist on schistosomula and adult Schistosoma mansoni worms. Mem Inst Oswaldo Cruz 108: 600–604.
83. Oxford AE, Raistrick H, Simonart P, (1939) Studies in the biochemistry of micro-organisms: Griseofulvin, C(17)H(17)O(6)Cl, a metabolic product of Penicillium griseo-fulvum Dierckx. Biochem J 33: 240–248.
84. Rathinasamy K, Jindal B, Asthana J, Singh P, Balaji P V, et al. (2010) Griseofulvin stabilizes microtubule dynamics, activates p53 and inhibits the proliferation of MCF-7 cells synergistically with vinblastine. BMC Cancer 10: 213.
85. Uen Y-H, Liu D-Z, Weng M-S, Ho Y-S, Lin S-Y, (2007) NF-kappaB pathway is involved in griseofulvin-induced G2/M arrest and apoptosis in HL-60 cells. J Cell Biochem 101: 1165–1175.
86. Ruge E, Korting HC, Borelli C, (2005) Current state of three-dimensional characterisation of antifungal targets and its use for molecular modelling in drug design. Int J Antimicrob Agents 26: 427–441.
87. Brian PW, (1949) Studies on the Biological Activity of Griseofulvin. Ann Bot 13: 59–77.
88. Da Silva Barros ME, de Assis Santos D, Hamdan JS, (2007) Evaluation of susceptibility of Trichophyton mentagrophytes and Trichophyton rubrum clinical isolates to antifungal drugs using a modified CLSI microdilution method (M38-A). J Med Microbiol 56: 514–518.
89. Chaudhuri a R, Ludueña RF, (1996) Griseofulvin: a novel interaction with bovine brain tubulin. Biochem Pharmacol 51: 903–909.
90. Czymmek KJ, Bourett TM, Shao Y, DeZwaan TM, Sweigard JA, et al. (2005) Live-cell imaging of tubulin in the filamentous fungus Magnaporthe grisea treated with anti-microtubule and anti-microfilament agents. Protoplasma 225: 23–32.
91. Rebacz B, Larsen TO, Clausen MH, Rønnest MH, Löffler H, et al. (2007) Identification of griseofulvin as an inhibitor of centrosomal clustering in a phenotype-based screen. Cancer Res 67: 6342–6350 doi:10.1158/0008-5472.CAN-07-0663
92. Jankovic J, Clarence-Smith K, (2011) Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother 11: 1509–1523.
93. Wimalasena K, (2011) Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry. Med Res Rev 31: 483–519.
94. Abdulla M-H, Ruelas DS, Wolff B, Snedecor J, Lim K-C, et al. (2009) Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening. PLoS Negl Trop Dis 3: e478 doi:10.1371/journal.pntd.0000478
95. Taft AS, Norante FA, Yoshino TP, (2010) The identification of inhibitors of Schistosoma mansoni miracidial transformation by incorporating a medium-throughput small-molecule screen. Exp Parasitol 125: 84–94.
96. Brugnara C, de Franceschi L, Alper SL, (1993) Inhibition of Ca(2+)-dependent K+ transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives. J Clin Invest 92: 520–526.
97. Yazejian B, Sun XP, Grinnell AD, (2000) Tracking presynaptic Ca2+ dynamics during neurotransmitter release with Ca2+-activated K+ channels. Nat Neurosci 3: 566–571.
98. Brayden JE, Nelson MT, (1992) Regulation of arterial tone by activation of calcium-dependent potassium channels. Science 256: 532–535.
99. Miyazaki T, Sagawa R, Honma T, Noguchi S, Harada T, et al. (2004) 73-kDa molecular chaperone HSP73 is a direct target of antibiotic gentamicin. J Biol Chem 279: 17295–17300.
100. Oskay Halacli S, Halacli B, Altundag K, (2013) The significance of heat shock proteins in breast cancer therapy. Med Oncol 30: 575.
101. Yang J, Yang L, Lv Z, Wang J, Zhang Q, et al. (2012) Molecular cloning and characterization of a HSP70 gene from Schistosoma japonicum. Parasitol Res 110: 1785–1793.
102. Levine SN, Hollier B, Aprindine inhibits calmodulin-stimulated phosphodiesterase and Ca-ATPase activities. J Cardiovasc Pharmacol 5: 151–156.
103. Tidow H, Nissen P, (2013) Structural diversity of calmodulin binding to its target sites. FEBS J 280: 5551–5565.
104. Katsumata T, Kohno S, Yamaguchi K, Hara K, Aoki Y, (1989) Hatching of Schistosoma mansoni eggs is a Ca2+/calmodulin-dependent process. Parasitol Res 76: 90–91.
105. Katsumata T, Shimada M, Sato K, Aoki Y, (1988) Possible involvement of calcium ions in the hatching of Schistosoma mansoni eggs in water. J Parasitol 74: 1040–1041.
106. Lewert RM, Hopkins DR, Mandlowitz S, (1966) The role of calcium and magnesium ions in invasiveness of schistosome cercariae. Am J Trop Med Hyg 15: 314–323.
107. Fusco AC, Salafsky B, Vanderkooi G, Shibuya T, (1991) Schistosoma mansoni: the role of calcium in the stimulation of cercarial proteinase release. J Parasitol 77: 649–657.
108. Salathe M, (2007) Regulation of mammalian ciliary beating. Annu Rev Physiol 69: 401–422.
109. Jaffe JJ, McCormack JJ, Meymarian E, (1972) Comparative properties of schistosomal and filarial dihydrofolate reductases. Biochem Pharmacol 21: 719–731.
110. Nessim NG, Hassan SI, William S, el-Baz H, (2000) Effect of the broad spectrum anthelmintic drug flubendazole upon Schistosoma mansoni experimentally infected mice. Arzneimittelforschung 50: 1129–1133 doi:10.1055/s-0031-1300336
111. Menezes CMS, Rivera G, Alves M a, do Amaral DN, Thibaut JPB, et al. (2012) Synthesis, biological evaluation, and structure-activity relationship of clonazepam, meclonazepam, and 1,4-benzodiazepine compounds with schistosomicidal activity. Chem Biol Drug Des 79: 943–949.
112. Angelucci F, Sayed AA, Williams DL, Boumis G, Brunori M, et al. (2009) Inhibition of Schistosoma mansoni thioredoxin-glutathione reductase by auranofin: structural and kinetic aspects. J Biol Chem 284: 28977–28985.
113. Li S, Wu L, Liu Z, Hu L, Xu P, et al. (1996) Studies on prophylactic effect of artesunate on schistosomiasis japonica. Chin Med J (Engl) 109: 848–853.